

R^3 is selected from the group R^{3b} consisting of
 H, C_{1-3} -alkyl-, cyclobutyl- and cyclopropyl-,
 wherein the above mentioned C_{1-3} -alkyl-, cyclobutyl- and cyclopropyl-
 groups may optionally be substituted with 1 to 7 substituents
 independently selected from the group consisting of halogen, C_{1-3} -
 alkyl-O-, NC- and HO-.

7. A compound according to any one or more of claims 1 to 6, wherein
 R^4 , R^5 are selected independently of each other from the group R^{4b}/R^{5b} consisting
 of
 H, halogen, HO-, H_3C -, F_3C -, H_3C -O-, F_2HC -O-, FH_2C -O-, F_3C -O-, C_{1-4} -
 alkyl-O-, R^7 -CH₂-O- and R^7 -(CH₂)₂-O-,
 wherein above mentioned C_{1-4} -alkyl-O-, R^7 -CH₂-O- and R^7 -(CH₂)₂-O-
 groups, may optionally be substituted with 1 to 5 substituents
 independently selected from the group consisting of halogen,
 optionally with 1 to 5 halogen atoms substituted C_{1-2} -alkyl-, and
 optionally with 1 to 5 halogen atoms substituted C_{1-2} -alkyl-O-.

8. A compound according to any one or more of claims 1 to ~~13~~7, wherein
 R^6 is selected from the group R^{6b} consisting of
 H, C_{1-4} -alkyl- and cyclopropyl-,
 wherein above mentioned C_{1-4} -alkyl-group may optionally be
 substituted with 1-9 fluorine and/or chlorine atoms.

wherein above mentioned C₃₋₆-cycloalkyl, heterocyclyl and heterocyclyl-C₁₋₃-alkyl-groups may optionally be substituted with 1 to 5 substituents independently selected from the group consisting of HO-, fluorine and optionally with 1 to 7 halogen atoms substituted C₁₋₃-alkyl-.


11. A compound according to any one or more of claims 1 to 10, wherein


R⁸ is selected from the group R^{8c1} consisting of


C₃₋₆-cycloalkyl and a saturated 4 to 6 membered monocyclic heterocycle containing one or two heteroatoms selected from N or O,

wherein above mentioned C₃₋₆-cycloalkyl and heterocyclyl-groups may optionally be substituted with 1 to 5 substituents independently selected from the group consisting of HO-, fluorine and optionally with 1 to 7 halogen atoms substituted C₁₋₃-alkyl-.

12. A compound according to any one or more of claims 1 to 11 selected from the group consisting of








the tautomers thereof, the stereoisomers thereof, the solvates thereof, the hydrates thereof and the salts thereof.

- 5 13. A compound according to any one or more of claims 1 to 12 of the formula




the tautomers thereof, the stereoisomers thereof, the solvates thereof, the hydrates thereof and the salts thereof.

- 10 14. A compound according to any one or more of claims 1 to 12 of the formula

the tautomers thereof, the stereoisomers thereof, the solvates thereof, the hydrates thereof and the salts thereof.


14. A compound according to any one or more of claims 1 to 12 of the formula



5


the tautomers thereof, the solvates thereof, the hydrates thereof and the salts thereof.

15. A compound according to any one or more of claims 1 to 12 of the formula



10 the tautomers thereof, the solvates thereof, the hydrates thereof and the salts thereof.


16. A compound according to any one or more of claims 1 to 12 of the formula



the tautomers thereof, the solvates thereof, the hydrates thereof and the salts thereof.


15

17. A compound according to any one or more of claims 1 to 12 of the formula




the tautomers thereof, the solvates thereof, the hydrates thereof and the salts thereof.

18. A compound according to any one or more of claims 1 to 12 of the formula




the tautomers thereof, the solvates thereof, the hydrates thereof and the salts thereof.

5 19. A compound according to any one or more of claims 1 to 12 of the formula



the tautomers thereof, the solvates thereof, the hydrates thereof and the salts thereof.


20. A compound according to any one or more of claims 1 to 12 of the formula



10


the tautomers thereof, the solvates thereof, the hydrates thereof and the salts thereof.

21. A compound according to any one or more of claims 1 to 12 of the formula




the tautomers thereof, the stereoisomers thereof, the solvates thereof, the hydrates thereof and the salts thereof.

22. A compound according to any one or more of claims 21-12 of the formula



the tautomers thereof, the solvates thereof, the hydrates thereof and the salts thereof.

23. A compound according to any one or more of claims 21-12 of the formula



the tautomers thereof, the solvates thereof, the hydrates thereof and the salts thereof.

24. A compound according to any one or more of claims 1 to 23, or a pharmaceutically acceptable tautomers thereof, stereoisomer thereof, mixtures thereof, solvate thereof, hydrate thereof or salt thereof for use as a medicament.

25. Pharmaceutical compositions containing at least one compound according to any one or more of the claims 1 to 23 or a pharmaceutically acceptable tautomers thereof, stereoisomer thereof, mixtures thereof, solvate thereof, hydrate thereof or salt thereof together with one or more pharmaceutically acceptable carrier.

26. A compound according to any one or more of claims 1 to 23, or a pharmaceutically acceptable tautomer thereof, stereoisomer thereof, mixtures thereof, solvate thereof, hydrate thereof or salt thereof or a pharmaceutical composition according to claim 25 for use in the prevention or treatment of (1) disorders comprising the symptom of cognitive

deficiency; (2) organic, including symptomatic, mental disorders, dementia; (3) mental retardation; (4) mood [affective] disorders; (5) neurotic, stress-related and somatoform disorders including anxiety disorders; (6) behavioural and emotional disorders with onset usually occurring in childhood and adolescence, attention deficit hyperactivity syndrome (ADHD) and Autism spectrum disorders; (7) disorders of psychological development, developmental disorders of scholastic skills; (8)

schizophrenia and other psychotic disorders; (9) disorders of adult personality and behaviour; (10) mental and behavioural disorders due to psychoactive substance use; (11) extrapyramidal and movement disorders; (12) episodic and paroxysmal disorders, epilepsy; (13) Systemic atrophies primarily affecting the central nervous system, ataxia; 5 (14) Behavioural syndromes associated with physiological disturbances and physical factors; (15) sexual dysfunction comprising excessive sexual drive; (16) factitious disorders; (17) Treatment, amelioration and / or prevention of cognitive impairment being related to perception, concentration, cognition, learning or memory; (18) Treatment amelioration and / or prevention of cognitive impairment being related to age- 10 associated learning and memory impairments; (19) Age-associated memory losses; (20) Vascular dementia; (21) Craniocerebral trauma; (22) Stroke; (23) Dementia occurring after strokes (post stroke dementia); (24) Post-traumatic dementia; (25) General concentration impairments; (26) Concentration impairments in children with learning and memory problems; (27) Alzheimer's disease; (28) Lewy body dementia; 15 (29) Dementia with degeneration of the frontal lobes; including Pick's syndrome; (30) Parkinson's disease; (31) Progressive nuclear palsy; (32) Dementia with corticobasal degeneration; (33) Amyotrophic lateral sclerosis (ALS); (34) Huntington's disease; (35) Multiple sclerosis; (36) Thalamic degeneration; (37) Creutzfeld-Jacob dementia; (38) HIV dementia; (38) Schizophrenia with dementia or Korsakoff's psychosis; (39) Sleep 20 disorders; (40) Bipolar disorder; (41) Metabolic syndrome; (42) Obesity; (43) Diabetes mellitus; (44) Hyperglycemia; (45) Dyslipidemia; (46) Impaired glucose tolerance; (47) Disease of the testes, brain, small intestine, skeletal muscle, heart, lung, thymus or spleen and (48) pain disorders.

27. A compound according to any one or more of claims 1 to 23, or a pharmaceutically 25 acceptable tautomer thereof, stereoisomer thereof, mixtures thereof, solvate thereof, hydrate thereof or salt thereof or a pharmaceutical composition according to claim 25 for use in symptomatic treatment of Alzheimer's Disease, symptomatic treatment of prodromal and/or mild-to-moderate Alzheimer's Disease and/or for the treatment of cognitive impairment associated with schizophrenia.